Biological Products, (No Diagnostic Substances) Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Biological Products, (No Diagnostic Substances)
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2019-01-17 | EDIT | Editas Medicine, Inc. | Myer Vickesh | CTO | S - Sale+OE | $26.36 | -7,000 | 0 | -100% | -$184,540 | |||||
| M | 2019-01-16 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.69 | +3,100 | 114,447 | +3% | +$2,131 | |||||
| A | 2019-01-15 | NSTG | Nanostring Technologies Inc | Allen Mary Tedd | SVP, Operations | S - Sale | $21.34 | -15,000 | 28,789 | -34% | -$320,130 | |||||
| D | 2019-01-14 | RUBY | Rubius Therapeutics, Inc. | Langer Robert | Dir | S - Sale+OE | $14.59 | -7,500 | 0 | -100% | -$109,444 | |||||
| M | 2019-01-16 | HSKA | Heska Corp | Napolitano Jason A | COO, Chief Strategist, Sec. | S - Sale | $90.70 | -7,500 | 24,538 | -23% | -$680,256 | |||||
| A | 2018-12-18 | CRSP | Crispr Therapeutics AG | Emster Kurt Von | Dir | S - Sale | $29.70 | -62,925 | 1,171,268 | -5% | -$1,869,168 | |||||
| D | 2019-01-16 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale+OE | $125.14 | -3,000 | 32,483 | -8% | -$375,428 | |||||
| D | 2019-01-16 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $124.25 | -1,900 | 26,842 | -7% | -$236,069 | |||||
| D | 2019-01-16 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale+OE | $9.27 | -3,046 | 0 | -100% | -$28,236 | |||||
2019-01-15 | OTLK | Outlook Therapeutics, Inc. | Mohan Pankaj | Dir, 10% | P - Purchase | $0.68 | +8,000 | 7,683,667 | 0% | +$5,440 | ||||||
2019-01-15 | RGNX | Regenxbio Inc. | Mills Kenneth T. | Pres, CEO | S - Sale | $43.85 | -15,000 | 201,000 | -7% | -$657,698 | ||||||
2019-01-15 | NSTG | Nanostring Technologies Inc | Allen Mary Tedd | SVP, Operations | S - Sale | $21.34 | -15,000 | 28,789 | -34% | -$320,130 | ||||||
| M | 2019-01-15 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $16.93 | -93,350 | 5,005,421 | -2% | -$1,580,637 | |||||
| M | 2018-11-19 | MBOT | Microbot Medical Inc. | Alliance Investment Management Ltd | 10% | P - Purchase | $3.70 | +102,309 | 1 | -100% | +$378,649 | |||||
| M | 2018-11-21 | MBOT | Microbot Medical Inc. | Alliance Investment Management Ltd | 10% | S - Sale | $9.00 | -402,628 | 1 | -100% | -$3,623,170 | |||||
2019-01-14 | ADAP | Adaptimmune Therapeutics Plc | Binder-Scholl Gwendolyn Knowlton | CTO | S - Sale | $5.37 | -1,514 | 2,487 | -38% | -$8,129 | ||||||
2019-01-14 | ADAP | Adaptimmune Therapeutics Plc | Bertrand William C Jr | COO | S - Sale | $5.37 | -2,271 | 3,731 | -38% | -$12,194 | ||||||
2019-01-14 | ADAP | Adaptimmune Therapeutics Plc | Amado Rafael | Pres, R, D | S - Sale | $5.37 | -3,028 | 4,974 | -38% | -$16,259 | ||||||
2019-01-14 | ADAP | Adaptimmune Therapeutics Plc | Rawcliffe Adrian | CFO | S - Sale | $5.37 | -3,084 | 3,318 | -48% | -$16,559 | ||||||
| M | 2019-01-14 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.71 | +6,665 | 111,347 | +6% | +$4,709 | |||||
| D | 2019-01-14 | BCRX | Biocryst Pharmaceuticals Inc | Powell Lynne | SVP - CCO | S - Sale+OE | $9.20 | -954 | 0 | -100% | -$8,777 | |||||
| D | 2019-01-15 | SGMO | Sangamo Therapeutics, Inc | Yi Kathy | SVP, CFO | S - Sale+OE | $11.04 | -5,000 | 7,250 | -41% | -$55,200 | |||||
2019-01-14 | VCEL | Vericel Corp | Michel Gerard J | CFO, VP, Corp. Development | S - Sale | $17.18 | -8,711 | 142,249 | -6% | -$149,627 | ||||||
2019-01-14 | SLDB | Solid Biosciences Inc. | Arnold Matthew Bennett | Dir | S - Sale | $32.00 | -5,000 | 3,386,293 | 0% | -$159,982 | ||||||
2019-01-11 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $17.40 | -40,392 | 5,098,771 | -1% | -$702,788 | ||||||
2019-01-10 | VICL | Vical Inc | Armistice Capital, LLC | 10% | S - Sale | $0.88 | -2,190,500 | 4,340,000 | -34% | -$1,930,707 | ||||||
| M | 2019-01-09 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.71 | +8,845 | 104,682 | +9% | +$6,275 | |||||
| M | 2019-01-09 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COO, Secretary | S - Sale | $20.37 | -7,500 | 685,827 | -1% | -$152,750 | |||||
| M | 2019-01-09 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $17.18 | -162,491 | 5,139,163 | -3% | -$2,791,433 | |||||
2019-01-09 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale | $20.04 | -30,000 | 104,213 | -22% | -$601,200 | ||||||
| D | 2019-01-08 | SGEN | Seattle Genetics Inc /wa | Gryska David W | Dir | S - Sale+OE | $65.04 | -5,000 | 45,050 | -10% | -$325,200 | |||||
| D | 2019-01-08 | SGEN | Seattle Genetics Inc /wa | Siegall Clay B | Pres, CEO | S - Sale+OE | $65.73 | -20,148 | 732,613 | -3% | -$1,324,237 | |||||
| M | 2019-01-09 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $34.55 | -7,800 | 737,363 | -1% | -$269,470 | |||||
2019-01-08 | NBIX | Neurocrine Biosciences Inc | Roberts Eiry | Chief Medical Officer | S - Sale | $84.09 | -1,857 | 3,143 | -37% | -$156,159 | ||||||
| A | 2018-11-15 | SLDB | Solid Biosciences Inc. | Schneider Joel Solomon Zev | See Remarks | S - Sale | $30.84 | -21,990 | 124,656 | -15% | -$678,180 | |||||
| A | 2018-12-03 | SLDB | Solid Biosciences Inc. | Amorrortu Pedro Alvaro | COO | S - Sale | $31.06 | -9,000 | 162,746 | -5% | -$279,534 | |||||
| A | 2019-01-04 | SLDB | Solid Biosciences Inc. | Amorrortu Pedro Alvaro | COO | S - Sale | $30.07 | -9,000 | 153,746 | -6% | -$270,619 | |||||
2019-01-08 | EDIT | Editas Medicine, Inc. | Bosley Katrine | Pres, CEO | S - Sale | $25.27 | -12,000 | 1,204,966 | -1% | -$303,240 | ||||||
| M | 2019-01-08 | CRSP | Crispr Therapeutics AG | Novak Rodger | Pres | S - Sale | $35.02 | -100,000 | 1,048,007 | -9% | -$3,502,385 | |||||
| M | 2019-01-07 | LJPC | La Jolla Pharmaceutical Co | Tang Kevin C | Dir, 10% | P - Purchase | $5.37 | +1,300,000 | 4,938,893 | +36% | +$6,985,285 | |||||
2019-01-07 | LJPC | La Jolla Pharmaceutical Co | Tidmarsh George F | Pres, CEO, Secretary | P - Purchase | $5.85 | +2,000 | 1,305,326 | 0% | +$11,700 | ||||||
2019-01-09 | LJPC | La Jolla Pharmaceutical Co | Carver Jennifer | COO | P - Purchase | $6.17 | +5,000 | 12,116 | +70% | +$30,825 | ||||||
2019-01-09 | LJPC | La Jolla Pharmaceutical Co | Rolke James | Chief Scientific Officer | P - Purchase | $6.09 | +1,600 | 76,330 | +2% | +$9,746 | ||||||
2019-01-07 | NITE | Nightstar Therapeutics Plc | Sundaram Senthil Vel | CFO | S - Sale | $12.98 | -406 | 127,277 | 0% | -$5,270 | ||||||
2019-01-07 | NITE | Nightstar Therapeutics Plc | Ong Tuyen | Chief Development Officer | S - Sale | $12.98 | -2,546 | 82,925 | -3% | -$33,049 | ||||||
2019-01-07 | NITE | Nightstar Therapeutics Plc | Robinson Gregory Scott | Chief Scientific Officer | S - Sale | $19.98 | -425 | 103,592 | 0% | -$8,492 | ||||||
2019-01-07 | NITE | Nightstar Therapeutics Plc | Fellows David A | CEO | S - Sale | $12.98 | -8,733 | 630,826 | -1% | -$113,361 | ||||||
| A | 2019-01-03 | NITE | Nightstar Therapeutics Plc | Ong Tuyen | Chief Development Officer | S - Sale | $12.00 | -4,070 | 85,471 | -5% | -$48,840 | |||||
| A | 2019-01-02 | NITE | Nightstar Therapeutics Plc | Robinson Gregory Scott | Chief Scientific Officer | S - Sale | $11.15 | -14,764 | 104,017 | -12% | -$164,619 | |||||
| M | 2018-08-15 | ENZN | Enzon Pharmaceuticals, Inc. | Couchman Jonathan | See Footnote 1, 10% | P - Purchase | $0.24 | +950,623 | 6,641,189 | +17% | +$230,187 | |||||
| M | 2018-04-13 | ENZN | Enzon Pharmaceuticals, Inc. | Couchman Jonathan | See Footnote 1, 10% | P - Purchase | $0.26 | +998,402 | 4,576,066 | +28% | +$258,606 | |||||
| M | 2019-01-07 | LJPC | La Jolla Pharmaceutical Co | Perceptive Advisors LLC | 10% | S - Sale | $5.69 | -2,060,235 | 2,253,376 | -48% | -$11,715,985 | |||||
2019-01-07 | BLUE | Bluebird Bio, Inc. | Walsh Jeffrey T. | Chief Financial | S - Sale | $113.64 | -3,012 | 32,483 | -8% | -$342,276 | ||||||
2019-01-07 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale | $113.64 | -7,374 | 210,389 | -3% | -$837,966 | ||||||
| D | 2019-01-07 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale+OE | $112.49 | -3,879 | 27,342 | -12% | -$436,363 | |||||
2019-01-07 | BLUE | Bluebird Bio, Inc. | Finger Alison Cecily | Chief Commercial Officer | S - Sale | $113.64 | -643 | 14,548 | -4% | -$73,068 | ||||||
| A | 2019-01-03 | BLUE | Bluebird Bio, Inc. | Finger Alison Cecily | Chief Commercial Officer | S - Sale | $99.31 | -476 | 15,191 | -3% | -$47,273 | |||||
2019-01-07 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale | $113.64 | -2,664 | 22,241 | -11% | -$302,734 | ||||||
2019-01-07 | BLUE | Bluebird Bio, Inc. | Cole Jason | GC | S - Sale | $113.64 | -1,416 | 20,194 | -7% | -$160,914 | ||||||
| M | 2019-01-07 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $16.42 | -134,174 | 5,301,654 | -2% | -$2,202,664 | |||||
| D | 2019-01-07 | FATE | Fate Therapeutics Inc | Tahl Cindy | GC, Secretary | S - Sale+OE | $16.00 | -25,000 | 90,418 | -22% | -$400,000 | |||||
| M | 2019-01-04 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.62 | +17,781 | 95,837 | +23% | +$11,082 | |||||
| D | 2019-01-07 | SGMO | Sangamo Therapeutics, Inc | Conner Edward R. | SVP, Chief Medical Officer | S - Sale+OE | $12.33 | -5,000 | 12,125 | -29% | -$61,631 | |||||
| D | 2019-01-04 | EDIT | Editas Medicine, Inc. | Hack Andrew A. F. | CFO | S - Sale+OE | $22.48 | -7,000 | 0 | -100% | -$157,360 | |||||
2019-01-07 | SLDB | Solid Biosciences Inc. | Arnold Matthew Bennett | Dir | S - Sale | $30.08 | -5,000 | 3,391,293 | 0% | -$150,407 | ||||||
2019-01-04 | SLDB | Solid Biosciences Inc. | Amorrortu Pedro Alvaro | COO | S - Sale | $30.07 | -9,000 | 158,046 | -5% | -$270,619 | ||||||
2019-01-04 | BCLI | Brainstorm Cell Therapeutics Inc. | Almenoff June Sherie | Dir | P - Purchase | $3.39 | +1,475 | 7,175 | +26% | +$5,000 | ||||||
2019-01-03 | NITE | Nightstar Therapeutics Plc | Ong Tuyen | Chief Development Officer | S - Sale | $12.00 | -4,070 | 4,070 | -50% | -$48,840 | ||||||
2019-01-03 | BLUE | Bluebird Bio, Inc. | Finger Alison Cecily | Chief Commercial Officer | S - Sale | $99.31 | -428 | 15,239 | -3% | -$42,506 | ||||||
| M | 2019-01-03 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $16.24 | -55,207 | 5,435,828 | -1% | -$896,359 | |||||
| DM | 2019-01-02 | DNLI | Denali Therapeutics Inc. | Ho Carole | Chief Medical Officer | S - Sale+OE | $19.55 | -14,502 | 217,267 | -6% | -$283,506 | |||||
| M | 2019-01-02 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $19.43 | -18,333 | 2,665,143 | -1% | -$356,288 | |||||
2019-01-02 | XLRN | Acceleron Pharma Inc | Kumar Ravindra | SVP, Chief Scientific Officer | S - Sale | $42.94 | -5,788 | 90,147 | -6% | -$248,546 | ||||||
2019-01-02 | XLRN | Acceleron Pharma Inc | Quisel John D | EVP, CBO, Secretary | S - Sale | $42.83 | -5,942 | 52,656 | -10% | -$254,490 | ||||||
2019-01-02 | XLRN | Acceleron Pharma Inc | McLaughlin Kevin F | SVP, CFO, Treasurer | S - Sale | $42.80 | -5,712 | 38,227 | -13% | -$244,494 | ||||||
2019-01-03 | XLRN | Acceleron Pharma Inc | Dable Habib J | CEO, Pres | S - Sale | $43.41 | -1,957 | 66,268 | -3% | -$84,961 | ||||||
2019-01-02 | NITE | Nightstar Therapeutics Plc | Robinson Gregory Scott | Chief Scientific Officer | S - Sale | $11.15 | -14,764 | 47,998 | -24% | -$164,619 | ||||||
| DM | 2019-01-02 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale+OE | $98.82 | -7,600 | 24,905 | -23% | -$751,060 | |||||
| D | 2019-01-02 | VCEL | Vericel Corp | Wotton Paul K | Dir | S - Sale+OE | $16.83 | -22,500 | 0 | -100% | -$378,693 | |||||
| AD | 2018-12-24 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir, 10% | P - Purchase | $0.75 | +3,333,332 | 2,642,151 | -482% | +$2,499,999 | |||||
| M | 2018-12-31 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.59 | +17,189 | 78,056 | +28% | +$10,142 | |||||
| D | 2019-01-02 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Tech. Operations Officer | S - Sale+OE | $35.00 | -1,500 | 31,858 | -4% | -$52,500 | |||||
2018-12-31 | CVM | Cel Sci Corp | Zimmerman Daniel H | SVP | S - Sale | $2.93 | -2,474 | 104,589 | -2% | -$7,249 | ||||||
2018-12-28 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $14.99 | -52,891 | 5,491,035 | -1% | -$792,751 | ||||||
2019-01-02 | AERI | Aerie Pharmaceuticals Inc | Kopczynski Casey C. | Chief Scientific Officer | S - Sale | $35.21 | -11,000 | 106,743 | -9% | -$387,313 | ||||||
| M | 2018-12-27 | ATRA | Atara Biotherapeutics, Inc. | Ciechanover Isaac E. | CEO | S - Sale | $33.88 | -7,800 | 745,163 | -1% | -$264,233 | |||||
| M | 2018-12-26 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.53 | +18,354 | 60,867 | +43% | +$9,651 | |||||
| M | 2018-12-26 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $14.66 | -100,000 | 5,543,926 | -2% | -$1,465,580 | |||||
2018-12-24 | BOLD | Audentes Therapeutics, Inc. | Lange Louis G | Dir | S - Sale | $18.62 | -32,000 | 379,933 | -8% | -$595,799 | ||||||
| AD | 2018-12-24 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir, 10% | P - Purchase | $0.75 | +3,333,332 | 2,636,151 | -478% | +$2,499,999 | |||||
| D | 2018-12-24 | BCDA | Biocardia, Inc. | Frost Phillip Md Et Al | 10% | P - Purchase | $0.75 | +2,000,000 | 12,875,318 | +18% | +$1,500,000 | |||||
| D | 2018-12-24 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $0.75 | +3,333,332 | 2,636,151 | -478% | +$2,499,999 | |||||
| M | 2018-12-21 | OTLK | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Dir | P - Purchase | $0.65 | +4,713 | 42,513 | +12% | +$3,075 | |||||
| AD | 2018-12-21 | WINT | Windtree Therapeutics Inc /de/ | Lee'S Pharmaceutical Holdings Ltd | 10% | P - Purchase | $4.00 | +9,874,799 | 15,715,141 | +169% | +$39,459,228 | |||||
| AD | 2018-12-21 | WINT | Windtree Therapeutics Inc /de/ | Lph II Investments Ltd | 10% | P - Purchase | $3.31 | +1,810,938 | 2,352,605 | +334% | +$5,994,205 | |||||
| M | 2018-12-20 | LIFE | Atyr Pharma Inc | Mendlein John | Dir | P - Purchase | $0.42 | +245,000 | 615,382 | +66% | +$103,247 | |||||
2018-12-21 | ACOR | Acorda Therapeutics Inc | Scopia Capital Management LP | 10% | S - Sale | $13.23 | -40,506 | 5,643,926 | -1% | -$536,097 | ||||||
2018-12-20 | FATE | Fate Therapeutics Inc | Nashat Amir | Dir | S - Sale | $12.25 | -33,474 | 1,823,186 | -2% | -$410,160 | ||||||
2018-12-24 | IDRA | Idera Pharmaceuticals, Inc. | Milano Vincent | Pres, CEO | P - Purchase | $2.93 | +15,000 | 55,816 | +37% | +$43,923 | ||||||
2018-12-21 | IDRA | Idera Pharmaceuticals, Inc. | Lim Bryant David | SVP, GC | P - Purchase | $3.05 | +4,000 | 4,743 | +538% | +$12,200 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |